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Abstract 
 
Dopamine dysregulation is one of the major hypotheses underlying the pathophysiology 
and treatment of schizophrenia, which is also widely accepted to be a neurodevelopmental 
disorder. Two well-established animal models based on prenatal environmental exposures 
– maternal immune activation (MIA) using poly(I:C) treatment, and developmental vitamin 
D deficiency (DVD) – both show an early reduction in factors crucial for dopaminergic 
development in the fetal brain. This is suggestive of a convergent aetiological mechanism, 
which is supported by our recent evidence showing that vitamin D can ameliorate 
schizophrenia-related behavioural phenotypes in the poly(I:C) model. We therefore wanted 
to investigate whether vitamin D is acting to correct the abnormal dopaminergic 
development induced by poly(I:C). Pregnant mice were co-administered the active vitamin 
D hormone simultaneously with poly(I:C) at gestational day 9 and embryos were collected 
at two developmental time-points, embryonic day 11 (E11) and E14. In order to examine 
dopamine ontogeny, we used immunohistochemistry to analyse the expression of two 
proteins, Lmx1a and Sox2, which can be used to distinguish dopamine progenitors and 
postmitotic neurons. Using spinning-disk confocal microscopy coupled with an optimised 
CellProfiler analysis pipeline, we were able to identify individual dopaminergic cells and 
quantify the expression of these markers, along with cell number, shape, size and spatial 
position. In E11 embryos, we showed that poly(I:C) impaired progenitor proliferation, with a 
reduction in the number of progenitors. While this was not directly rescued by vitamin D, 
some neuroprotective effects were observed; vitamin D increased Lmx1a expression in 
progenitors and normalised the lateral positioning of postmitotic cells. These alterations 
were transient, as we did not observe any effects of treatment at E14. Analysis of 
additional markers which are present in differentiated dopamine neurons is required to 
understand whether MIA and vitamin D are affecting later aspects of dopaminergic 
development. We hope to use these findings to elucidate how different environmental risk 
factors for schizophrenia converge on developing dopaminergic systems. 
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Chapter 1: Introduction 
 
1.1 Schizophrenia 
 
1.1.1 What is schizophrenia? 
 
Schizophrenia is a severely disabling neuropsychiatric disorder. As it tends to persist 
throughout a person’s life with pervasive deficits, it is one of the main causes of disability 
worldwide (Tandon et al., 2008; WHO, 2011). Moreover, people with schizophrenia have 
an increased risk of premature death, due to higher suicide rates, unequal access to 
healthcare and increased frequency of routine risk factors, resulting in additional chronic 
health conditions (van Os and Kapur, 2009; WHO, 2011). The most prevalent treatment is 
anti-psychotic medication, which only address a subset of symptoms and in fact are 
associated with serious side effects, further contributing to mortality risks (Saha et al., 
2007).  
 
The symptoms of schizophrenia can be clustered into three main categories: 1) psychosis, 
or the positive-symptom dimension, which encompasses delusions and hallucinations; 2) 
the negative-symptom dimension, which describes deficiencies in functions normally 
present, such as apathy, asociality, anhedonia and alogia, and 3) the cognitive-symptom 
dimension, which includes difficulties in memory, attention and executive function (van Os 
and Kapur, 2009; George and Klijn, 2013). However, there is a debate as to whether the 
concept of schizophrenia as a distinct disease is particularly useful anymore and could in 
fact be detrimental to mental health practices. In a recent review, Guloksuz and van Os 
thoroughly outline the main issues surrounding the term, regarding it as “a psychiatric 
tradition as much as a diagnosis” (Guloksuz and van Os, 2017). The idea of a psychosis 
spectrum disorder has emerged as a better alternative; it encompasses the heterogeneity 
of psychopathology, treatment response and outcome, and would reframe psychosis in a 
way that is not exclusive to schizophrenia  (Os, 2016; Guloksuz and van Os, 2017). Even 
as the concept of schizophrenia evolves in the clinical realm, the underlying biological 
mechanisms will not change and one of the most enduring hypotheses posits a central 
role of dopamine.  
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1.1.2 1 The dopamine hypothesis 
 
The dopamine (DA) hypothesis of schizophrenia emerged in the 1960s, initially proposing 
that excessive DA transmission was responsible for the disorder (van Rossum, 1966). This 
stemmed from work highlighting the importance of dopamine-receptor blockade in the 
mechanism of action of antipsychotic drugs (van Rossum, 1966). This idea was further 
substantiated by studies showing that DA agonists worsen psychotic symptoms, and the 
correlation between clinical doses of antipsychotic drugs and their affinity for DA D2 
receptors (Seeman and Lee, 1975; Creese et al., 1976; Angrist and Van Kammen, 1984). 
This classical DA hypothesis was centred on subcortical brain regions, as this is where 
most DA terminals and D2 receptors are found. One of the major drawbacks of this 
hypothesis was its focus on the positive symptom dimension, with negative and cognitive 
symptoms unresponsive to D2 receptor antagonism. In 1991, Davis et al. proposed a 
second iteration of the DA hypothesis, whereby hypodopaminergia in the prefrontal cortex 
was responsible for negative/deficit symptoms, and led to subcortical hyperdopaminergia, 
resulting in positive symptoms (Davis et al., 1991). This hypothesis was based not only on 
pharmacological evidence, but took into account post-mortem, metabolite and animal 
studies. While this theory was an important step forward in understanding the 
pathophysiology of schizophrenia, particularly disentangling regional differences in DA 
abnormalities, the authors still acknowledged that it would undoubtedly prove ‘overly 
simplistic’.  
 
Eighteen years later, following advances in imaging techniques, genetics and 
understanding environmental risk factors, a third version of the DA hypothesis was put 
forward (Howes and Kapur, 2009). One of the major developments was narrowing the 
locus of DA dysfunction to elevation in presynaptic striatal dopaminergic function, and 
linking this specifically to psychosis rather than schizophrenia as a whole (Howes et al., 
2012). Secondly, it was proposed that multiple environmental and genetic risk factors 
interact and converge to result in this DA dysregulation – “the final common pathway” 
(Murray et al., 2017). It is also important to note that DA dysfunction is present prior to 
diagnosis; a number of studies have shown that increased DA synthesis capacity is 
present in people at clinical high risk of psychosis, referred to as the ‘prodromal’ period 
(Howes et al., 2009; Fusar-Poli et al., 2011; Egerton et al., 2013). This dysregulation 
progressively increases with the development of acute psychosis  (Howes et al., 2011). As 
technology rapidly progresses and techniques become more advanced, new data will 
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continue to revise and refine this hypothesis. However, what is still unclear is how aberrant 
DA signalling in the adult patient can be reconciled with a disorder of early brain 
development. 
 
1.1.3 The neurodevelopmental hypothesis  
 
Schizophrenia is widely accepted to have neurodevelopmental origins, whereby the illness 
is the end stage of a series of disruptions to the developing pre- and postnatal brain, long 
before the onset of symptoms during adulthood (McGrath et al., 2003; Rapoport et al., 
2012). According to this model, an interaction between these neurodevelopmental 
perturbations and periadolescent maturation processes precipitates the emergence of 
psychosis (Meyer and Feldon, 2010). This model is strongly supported by evidence from 
epidemiological studies which demonstrate an association between pre- and perinatal 
environmental factors and schizophrenia risk. A variety of different environmental factors 
have been implicated, including maternal exposure to infections, nutritional deficiencies 
and stress, obstetric complications and advanced paternal age (Brown, 2011; Owen et al., 
2016). These environmental insults occur during critical periods of brain development, 
thereby altering neurodevelopmental trajectories and predisposing an individual to long-
term changes in brain function (Meyer and Feldon, 2010). When the neurodevelopmental 
hypothesis first emerged in the 1980s, the prenatal event was described as a ‘fixed lesion’ 
which remained clinically dormant until interacting with normal brain maturational 
processes later in life (Weinberger, 1987). More recent imaging studies point towards a 
progressive neurodevelopmental disorder, whereby dynamic changes occur during the 
transition to illness, possibly mediated by environmental factors such as drug abuse and 
stress (McGrath et al., 2003; Pantelis et al., 2005). Thus, early insults, which are often 
restricted and highly transient, can lead to subtle alterations in circuitry and 
neurochemistry that are vulnerable to later-occurring stressors (Thompson and Levitt, 
2010). Based on epidemiologically-informed environmental risk factors, 
neurodevelopmental animal models have been established which provide a sound 
experimental platform for elucidating the developmental mechanisms underpinning 
schizophrenia. In the following sections, I will describe two of these models with an 
emphasis on the role of DA. 
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1.2 Maternal immune activation (MIA) model 
 
There is extensive epidemiological evidence that gestational exposure to infection is 
associated with an increased risk for schizophrenia. A number of different infectious 
agents have been implicated, including influenza (Brown et al., 2004), rubella (Brown et 
al., 2001), Toxoplasma gondii (Mortensen et al., 2007), herpes simplex (Buka et al., 2001),  
as well as bacterial pathogens (Sørensen et al., 2009). This suggests that the association 
between prenatal infection and schizophrenia is mediated by factors common to the 
immune response (Brown and Derkits, 2010; Meyer and Feldon, 2010). These 
epidemiological findings have driven the development of several  ‘immuno-precipitated’ 
neurodevelopmental animal models (Meyer and Feldon, 2012). One of the earliest models 
was pioneered by Fatemi and colleagues, which involved exposing pregnant mice to the 
human influenza virus (Fatemi et al., 1999). Another class of models which followed 
utilises immune-activating agents, namely the bacterial endotoxin LPS 
(lipopolysaccharide) and the synthetic viral analogue poly(I:C) (polyriboinosinic-
polyribocytidilic acid), which effectively mimic inflammatory cytokine-associated immune 
responses (Meyer, 2014). Here I will focus on the poly(I:C) model, which has become a 
widely recognised maternal immune activation (MIA) model throughout the world, and the 
model I have used in this project (Meyer and Feldon, 2012).   
 
The rodent poly(I:C) model involves systemic exposure of pregnant dams to poly(I:C) at a 
specific gestational age. Poly(I:C) is recognised by the immune system through toll-like 
receptor 3 (TLR3) and induces the release of a number of pro-inflammatory cytokines, 
including interleukin (IL)-1β, IL-6 and tumour necrosis factor (TNF)-α, as well as type I 
interferons (IFNs) (Boksa, 2010). Using poly(I:C) instead of a live viral pathogen confers 
control over the time-course of exposure, as poly(I:C)-induced immune reactions are 
restricted to 24-48 hours depending on the dose used (Meyer et al., 2005; Cunningham et 
al., 2007). This allows the experimenter to probe critical windows of vulnerability 
corresponding to specific periods of fetal development, with studies suggesting that early 
gestation exposure results in more severe postnatal abnormalities compared to late 
gestation (Meyer et al., 2007; Meyer, 2014). 
 
Substantial work has been done towards understanding the behavioural, structural and 
neurochemical consequences of maternal poly(I:C) treatment in the resulting offspring, 
throughout postnatal development into adulthood (summarised in detail by Meyer and 
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Feldon, 2010 and Boksa, 2010). Many of the behavioural dysfunctions are implicated in 
critical schizophrenia phenotypes, including deficits in sensorimotor gating, selective 
attention, social interaction, working memory and cognitive flexibility, as well as sensitivity 
to psychostimulant drugs (Zuckerman et al., 2003; Meyer et al., 2005; Ozawa et al., 2006; 
Luchicchi et al., 2016). Interestingly, a number of these behavioural outcomes only 
emerge in post-pubertal, but not pre-pubertal animals, which is in accordance with the 
progression of pathological symptoms in human patients (Vuillermot et al., 2010). 
Consistent with the predictive validity of this model, some of these behavioural deficits can 
be normalised using antipsychotic drug treatment (Ozawa et al., 2006). In terms of 
structural changes relevant to schizophrenia, increased lateral ventricle volume has been 
observed in poly(I:C) offspring, which is one of the most consistent findings in patients (Li 
et al., 2009; Kempton et al., 2010). With regards to neurochemical findings, supportive of 
the DA hypothesis, a number of different studies have found a host of dopaminergic 
changes, including increased DA release from striatal slices, increased striatal tyrosine 
hydroxylase (TH), D2R expression and DA turnover, increased DA in the prefrontal cortex 
(PFC) and globus pallidus, and decreased D1R expression in the medial PFC (Zuckerman 
et al., 2003; Ozawa et al., 2006; Winter et al., 2009; Vuillermot et al., 2010; Luchicchi et 
al., 2016). Additionally, poly(I:C)-induced sensitivity to the DA agonist amphetamine is 
present at the pre-pubertal stage, which is in line with the early dysfunction in DA observed 
in prodromal patients (Vuillermot et al., 2010).  
  
The mechanisms responsible for transducing in utero poly(I:C) exposure to long-term 
postnatal changes have yet to be fully elucidated. One of the prime candidates is aberrant 
cytokine signalling, as cytokines are recognised to play important neurodevelopmental 
roles (Patterson, 2002; Deverman and Patterson, 2009). In support of this theory, it has 
been demonstrated that IL-6 is a critical mediator of poly(I:C)-induced behavioural 
changes. For instance, co-administration of an IL-6 antibody with poly(I:C) prevented 
deficits in pre-pulse inhibition (PPI), latent inhibition (LI), exploratory and social behaviour; 
additionally, poly(I:C) failed to induce several behavioural phenotypes in IL-6 knockout 
mice (Smith et al., 2007). More recently, it has been shown that treatment with an IL-17a 
antibody can ameliorate additional MIA-induced behavioural deficits (Choi et al., 2016). 
Meyer et al. have demonstrated a neuroprotective role of the anti-inflammatory cytokine IL-
10 in the poly(I:C) model, while IL-10 on its own precipitated behavioural abnormalities; 
this led to the proposal that an imbalance of pro- and anti-inflammatory cytokine signalling 
represented a key mechanism involved in MIA (Meyer et al., 2008; Meyer, Feldon and 
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Yee, 2009). As Meyer points out however, the acute effects of prenatal inflammation on 
fetal brain development have not been well-studied (Meyer, 2013). It is possible that these 
early inflammatory events could in fact induce primary defects in developing 
neurotransmitter systems with subsequent long-term consequences, as will be discussed 
in section 1.4.  
 
1.3 Developmental vitamin D (DVD) deficiency  
 
There is strong evidence which suggests a link between developmental vitamin D (DVD) 
deficiency and schizophrenia. This evidence stems from epidemiological studies, which 
have found higher incidence rates of schizophrenia associated with winter and spring 
births, at higher latitudes, in migrant groups with dark-skin and in urban settings; factors 
that can be tied together by a lack of vitamin D (McGrath et al., 2010). This link was further 
substantiated by a population-based case-control study which showed that neonatal 
vitamin D status was significantly associated with schizophrenia (McGrath et al., 2010).  
 
Based on these findings, a rodent model of DVD deficiency was created, which 
demonstrates a host of significant changes in brain development and behaviour (Eyles et 
al., 2013). These include an increase in lateral ventricle size, increased cellular 
proliferation and reduced apoptosis throughout the developing brain, and altered 
neurogenesis (Eyles et al., 2003; Ko et al., 2004; Cui et al., 2007). Adult DVD deficient rats 
have demonstrated behavioural phenotypes of relevance to schizophrenia, which overlap 
with those observed in the MIA model. These include hyperlocomotion in response to a 
novel open field, sensitivity to DA and NMDA antagonists and impaired LI (Burne et al., 
2004; Becker et al., 2005; Kesby et al., 2006, 2010). 
 
Multiple lines of evidence have shown that vitamin D plays important roles in the 
developing brain, influencing neuronal differentiation (Eyles et al., 2003; Cui et al., 2007) 
and axonal growth (Brown et al., 2003), and regulating calcium (Brewer et al., 2001), 
reactive oxygen species (Garcion et al., 2002) and neurotrophic factors (Gezen-Ak et al., 
2011). The active vitamin D hormone, 1,25-dihydroxy vitamin D3 (1,25(OH)2D3 or 
1,25OHD), signals through the vitamin D receptor (VDR) via genomic and non-genomic 
pathways (Cui et al., 2017). The VDR is expressed in the adult human brain in a similar 
distribution to that reported in rodents, and importantly, it is abundant in DA neurons in the 
substantia nigra (SN) (Eyles et al., 2005; Cui et al., 2013). In rats, the VDR first appears 
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from embryonic day 12 (E12) with increasing expression in the midbrain until weaning; as 
most DA neurons are born between E11-E14 in the rat midbrain, this is suggestive of a 
potential role for vitamin D in dopaminergic development (Cui et al., 2013). Additionally, in 
vitro studies have shown that vitamin D is involved in regulating the expression of genes 
related to DA neuron development and maintenance (Pertile et al., 2016). In the next 
section, I will discuss evidence for early alterations in DA ontogeny observed in both the 
MIA and DVD models.   
 
1.4 Convergence between models on early aspects of DA development 
 
In order to understand how gestational exposures result in postnatal pathologies, it is 
important to examine what effect these exposures are having on the developing brain. 
Considering the centrality of DA in the pathophysiology of schizophrenia, and the 
functional and structural DA abnormalities observed in the animal models discussed 
above, it is possible that disrupted DA development may represent a primary aetiological 
mechanism (Meyer and Feldon, 2009; Eyles et al., 2012). 
 
In a study examining the acute effects of MIA on developing DA systems, pregnant mice 
were administered poly(I:C) at gestational day (GD) 9 and embryos were examined 2, 4 
and 8 days later (Meyer et al., 2008). These time-points correspond with the initial peak of 
DA cell birth in the mouse, E11, and early and late postmitotic periods, E13 and E17 
(Bayer et al., 1995; Prakash and Wurst, 2006). A significant increase in the number of 
midbrain DA (mDA) neurons in the fetal brain was observed at E13 and E17. Gene 
expression levels (in whole brains) of fibroblast growth factor 8 (Fgf8) and sonic hedgehog 
(Shh) were also altered, two secreted factors involved in the induction of the midbrain and 
mDA progenitor domain (Blaess and Ang, 2015). In addition, the expression of two 
transcription factors involved in the specification and maturation of DA neurons, nuclear 
receptor related-1 (Nurr1) and pituitary homeobox 3 (Pitx3), were reduced at E11 but 
normalised by E13.  
 
Interestingly, similar alterations in factors involved in DA ontogeny have been observed in 
the DVD model. Looking specifically at the fetal midbrain of embryos derived from vitamin 
D deficient rats, a significant reduction in Nurr1 was observed at E12 and E15 (Cui et al., 
2010). As rat development occurs 1-2 days later than that of mice, this corresponds with 
the maximal and immediate postmitotic period of DA cell birth in the rat (Gates et al., 2006; 
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Prakash and Wurst, 2006). The cyclin-dependent kinase inhibitor p57Kip2, which functions 
cooperatively with Nurr1 in promoting mDA differentiation (Joseph et al., 2003), was also 
reduced at E12. Additionally, there was a trend for a reduction in TH at E12, while a more 
dramatic reduction was observed in E17.5 embryos from DVD-deficient mice (Hawes et 
al., 2015). In a recent study using more advanced quantitative microscopy techniques in 
the rat model, Nurr1 was found to be reduced specifically in the ventral tegmental area 
(VTA) at E15, while TH was reduced in the SN, with no changes in cell number, 
morphology or positioning (Luan et al., 2017).   
 
Considering this evidence from the MIA and DVD models, it appears that both of these 
maternal exposures act to reduce factors required for early dopaminergic development at 
critical periods of DA neurogenesis. Whether vitamin D or poly(I:C)-induced cytokines are 
involved in directly regulating these factors or if indirect mechanisms are involved is still 
unclear (Eyles et al., 2012). Overall, this is suggestive of a convergent mechanism by 
which these two prenatal environment exposures can lead to postnatal DA-related 
abnormalities. Given this convergence and the potential role of vitamin D in DA 
development, as well as its well-established anti-inflammatory actions (Krishnan and 
Feldman, 2011), our lab group decided to investigate the effect of this modifiable factor in 
the poly(I:C) model. 
 
1.5 Vitamin D in the poly(I:C) model 
 
In a recently published study, vitamin D was co-administered with poly(I:C) to pregnant 
dams at GD9 and several behavioural phenotypes were examined in juvenile offspring 
(Vuillermot et al., 2017). Although this study was focussed on autism-related behaviours, 
there is overlap with schizophrenia-related phenotypes, including deficits in social 
interaction and learning. Vitamin D was shown to completely rescue poly(I:C)-induced 
behavioural deficits; specifically, social approach, stereotyped digging and acquisition and 
expression of tone-cued fear conditioning. Additionally, vitamin D was able to prevent 
amphetamine-induced hyperlocomotion in poly(I:C)-treated animals (unpublished data). As 
described earlier, the long-term effects of MIA are believed to be mediated by 
inflammatory cytokines; one therefore might expect that vitamin D may be acting to 
suppress the production of these cytokines. In fact, vitamin D has been shown to 
downregulate the expression of IL-6 and TNF-α in prostate cells and monocytes by 
targeting MAP kinases (Nonn et al., 2006; Almerighi et al., 2009; Zhang et al., 2012). 
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Subsequently, the authors of this study decided to measure the levels of three of the major 
poly(I:C)-induced cytokines four hours post-treatment, which corresponds with the peak 
cytokine response (Meyer et al., 2006). While poly(I:C) led to a marked increase in IL-1β, 
IL-6 and TNF-α in both maternal blood and fetal brains, vitamin D co-administration had no 
effect of any of these cytokine levels. This suggests that vitamin D is not acting via an anti-
inflammatory pathway in response to maternal immune challenge but perhaps a more 
direct neuroprotective mechanism. 
 
It is important to note that only male offspring were examined in this study, in order to 
“circumvent interpretative limitations arising from hormonal fluctuations in females” 
(Vuillermot et al., 2017). To follow on from this study, and in accordance with most studies 
using the MIA model (Hill, 2016), this project only examined male embryos. However, 
future studies will be conducted on the female embryos which were also collected, as it is 
important to consider potential sex-specific vulnerabilities. In the few MIA studies which 
have examined females, some behavioural sex differences were apparent, pointing 
towards the male PFC being more vulnerable to early developmental disruptions (Hill, 
2016). Interestingly, one study looking at prenatal exposure to IL-1β found female specific 
behavioural phenotypes alongside reduced progesterone turnover in the hippocampus, 
suggesting potential interactions between inflammatory cytokines and sex steroids which 
could influence the developing brain and resulting behavioural outcomes  (Paris et al., 
2011; Hill, 2016). Additionally, there are studies pointing towards sex differences in 
mesolimbic DA systems; for example, DVD has been shown to selectively affect DA-
mediated behaviours and DA transporter function in females but not males (Kesby et al., 
2010). It would therefore be highly important to investigate potential sex differences in 
developing dopaminergic systems.  
 
1.6 Dopamine development 
 
Before describing the aims of this project, which focus on dopamine ontogeny, I would like 
to provide a brief overview of some of the key factors involved in dopaminergic 
development in mice. DA neurons originate in the midbrain floor plate (FP), which consists 
of distinct zones containing subsets of the DA lineage (Arenas et al., 2015). The 
emergence of the mDA progenitor domain in the ventricular zone is characterised by the 
expression of Lmx1a at around E9 in the mouse (Andersson et al., 2006). Lmx1a is a LIM 
homeodomain transcription factor required for the specification, proliferation and 
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differentiation of DA progenitors (Blaess and Ang, 2015). Lmx1a is upregulated by the 
Wnt1/β-catenin pathway in an autoregulatory fashion and one of its downstream targets 
includes Nurr1 (Chung et al., 2009). As mentioned earlier, Nurr1 is a crucial regulator of 
DA neuron specification, as well as long-term survival; it begins to be expressed from 
E10.5 in immature postmitotic neurons migrating ventrally into the intermediate zone 
(Hegarty et al., 2013). Nurr1 regulates a number of genes which define a DA neuron, 
including TH, the rate-limiting enzyme of DA synthesis (Lévesque, 2013). Mature DA 
neurons expressing TH are found in the mantle zone, from which they undergo radial and 
tangential migration to their final positions, ultimately forming the VTA and SN (Blaess and 
Ang, 2015).   
 
An additional protein examined in this project was Sox2. Sox2 is a member of the SoxB1 
subfamily of transcription factors, which universally mark neural progenitor and stem cells 
in the vertebrate central nervous system (CNS), including the developing midbrain 
(Graham et al., 2003; Blaess and Ang, 2015). It is necessary for maintaining the 
proliferative capacity of progenitors and inhibiting neuronal differentiation (Graham et al., 
2003). Sox2 is not specific to mDA progenitors and was used to differentiate progenitors 
from postmitotic cells in conjunction with Lmx1a. 
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1.7 Aims & hypothesis 
 
The aim of this project was to investigate whether vitamin D can correct the abnormal 
dopaminergic development induced by poly(I:C). This could represent a putative 
neuroprotective mechanism by which vitamin D is able to rescue the downstream 
postnatal changes observed in the MIA model. I investigated two developmental time-
points, E11 and E14, following poly(I:C) and vitamin D administration at GD9. I used 
immunohistochemistry to examine the expression of Lmx1a and Sox2, thereby analysing 
two cell populations, progenitors (Lmx1a+Sox2+) and postmitotic cells (Lmx1a+Sox2-). I 
used an automated CellProfiler pipeline to identify individual dopaminergic cells and 
quantify the expression of these markers, as well as cell number, shape, size and spatial 
position. 
 
This project focussed on the proximal effects of poly(I:C) and vitamin D on developing DA 
systems. These are two acute exposures; the sickness behaviour and peripheral cytokines 
induced by poly(I:C) peak after 3 hours, with animals fully recovered after 24 hours, while 
the half-life of vitamin D is less than 6 hours (Healy et al., 2003; Cunningham et al., 2007).  
My hypothesis was that poly(I:C) would disrupt early aspects of DA ontogeny, possibly by 
reducing the expression of Lmx1a or altering some aspect of progenitor function, which 
could then lead to significant downstream effects on DA development, such as the 
previously observed reduction in Nurr1. I hypothesised that vitamin D may be acting to 
restore the expression of these factors and facilitate the progression of mDA progenitors to 
functional DA neurons.  
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Chapter 2: Materials and Methods 
 
2.1 Breeding 
C57BL/6J mice (Animal Resource Centre, Western Australia) were used throughout the 
study. Animals were housed in a 12-h light/dark cycle (lights on at 07:00 h). Females were 
group-housed for 2 weeks prior to mating in order to suppress estrous, then exposed to 
male bedding 2 days prior to mating to induce estrous. Breeding occurred at night; one 
male was placed with one female starting at 23:00 h, then removed 3 hours later. This 
restricted breeding window was adopted due to considerable variation in the age of 
embryos collected for preliminary experiments from standard time-mated dams (Appendix 
1). Initially, each female was checked for the presence or absence of a sperm plug in order 
to identify which would become pregnant. However, there was a very low conversion of 
positive plug detection to successful pregnancy, with the rate being around 30%. For 
subsequent breeding waves, a weight gain discrimination method was used to determine 
pregnancy, following a recently published protocol (Heyne et al., 2015). Additionally, rather 
than exposure to male bedding, males and females were placed in split housing (1 male to 
1-2 females) four days prior to mating. Females were weighed on the day of breeding, 
then again on GD7 and GD8. Those which reached the optimal weight gain threshold of 
1.75g were considered pregnant. This increased the pregnancy detection rate to around 
55%.   
 
2.2 Prenatal treatment 
Pregnant dams on GD9 were first injected intravenously (into the tail vein) with either 
poly(I:C) (POL) or saline solution (CON) and then immediately injected subcutaneously 
with either 1,25OHD (VITD) or vehicle (VEH); thus, the dams were divided into 4 treatment 
groups: CON/VEH, POL/VEH, CON/VITD, POL/VITD.  
 
Poly(I:C) (potassium salt; Sigma-Aldrich, Australia; 5mg/kg) was dissolved in sterile 
pyrogen free 0.9% NaCl (B.Braun, USA) to yield a final concentration of 1mg/ml. Dams 
were injected with a volume of 5ml/kg; the dose was calculated based on previous dose-
response studies (Meyer et al., 2005). The animals were mildly restrained in an injection 
cone and the success of the injection was determined by the experimenter, as described 
previously (Vuillermot et al., 2010).  
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1,25OHD (solid powder, Millipore, Australia) was dissolved in 100% ethanol to make a 
100ng/µl stock solution. To make the drug delivery solution, 4µl of 1,25OHD stock solution 
was added to 2ml of sterile corn oil (Sigma-Aldrich, USA) and vortexed thoroughly (vehicle 
was prepared as 4µl 100% ethanol instead of 1,25OHD). Dams were injected with a 
volume of 2ml/kg; this dose was based on a previous study, which ensured there were no 
adverse effects on pup development or dam health (Vuillermot et al., 2017).  
 
Following injections, dams were monitored every hour for 6 hours, then after 24 hours, to 
assess poly(I:C)-induced sickness behaviour, and scored according to a given set of 
criteria, with the observer blind to treatment group (Appendix 2).   
 
2.3 Tissue collection  
Tissue was collected at E11 and E14, from separate cohorts of animals. Pregnant dams 
were euthanised by decapitation, maternal blood was collected and fetuses were 
immediately removed from the uteri. The fetal head region was separated from the body, 
and tails/limbs were collected for later sex determination. For E11 embryos, the whole 
head was immersion fixed in 4% paraformaldehyde overnight at 4ºC. For E14 embryos, 
the brain was extracted under a dissection-microscope before fixation. Fixed specimens 
were soaked in 30% sucrose solution for at least 48 hours before being embedded in 
Tissue-Tek O.C.T compound (Sakura Finetek, USA). Samples were stored at -80ºC until 
further processing. 
 
2.4 Sex determination 
To determine the sex of the collected embryos, PCR was performed using a primer pair 
that amplifies fragments from the X and Y chromosomes, resulting in different sized 
products for males and females (McFarlane et al., 2013; Appendix 3). The primer pair had 
the following sequences:  
SX_F: 5ʹ-GATGATTTGAGTGGAAATGTGAGGTA-3ʹ 
SX_R: 5ʹ-CTTATGTTTATAGGCATGCACCATGTA-3ʹ  
DNA was extracted from tail/limb tissue using a DNeasy Blood & Tissue Kit (Qiagen, 
Australia). PCR reactions were performed in a final volume of 25µl, with 1x PCR buffer, 
1.5mM MgCl2, 0.2mM dNTPs, 0.5µM forward and reverse primers, 1 unit Taq polymerase 
(Invitrogen, Australia) and 4µl template DNA. The following PCR parameters were used; 
initial denaturation at 94ºC for 3 mins, 30 cycles with denaturation at 94ºC for 45 secs, 
annealing at 55ºC for 30 secs, extension at 72ºC for 4.5 mins, followed by final extension 
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at 72ºC for 10 mins. PCR products were analysed using gel electrophoresis on 2% 
agarose gels stained with SYBR Green dye (Invitrogen, Australia), together with a 1kb 
DNA ladder (Invitrogen, Australia), and visualised under UV-illumination. 
 
2.5 Immunohistochemistry 
Two male embryos per litter were randomly chosen from 6 litters for each experimental 
group (48 in total). Brains were sectioned using a cryostat, and 20µm coronal sections 
were collected from the entire midbrain region; for E11 embryos, a 1 in 3 series was used 
and for E14 embryos, a 1 in 6 series was used. For immunostaining, the sections were 
rinsed in phosphate-buffered saline (PBS) and blocked for 4-6 hours in 10% normal 
donkey serum (NDS) in PBS with Triton X-100 (Sigma-Aldrich, Australia, PBST). The 
following primary antibodies were used: rabbit anti-Sox2 (1:200, Millipore, Australia), goat 
anti-Lmx1a (1:100, Santa Cruz, USA), rabbit anti-Nurr1 (1:500, Santa Cruz, USA) and 
sheep anti-TH (1:100, Novus Biology, Australia). All sections from each experimental 
group were processed at the same time for Lmx1a-Sox2 and Nurr1-TH. This was done in 
order to exclude batch variation and ensure the staining was comparable between slides 
for the quantitative analysis of protein expression (described below). Primary antibodies 
were diluted in blocking solution and incubated overnight at room temperature. After 4 
washes with PBST (15 min each), the sections were incubated with fluorophore-
conjugated secondary antibodies diluted in blocking solution, for 4-6 hours at room 
temperature. The following secondary antibodies were used: Alexa-555 conjugated 
donkey anti-goat (1:1000, Thermo Fisher Scientific, USA), Alexa-647 conjugated donkey 
anti-rabbit (1:1000, Thermo Fisher Scientific, USA) and Alexa-488 conjugated donkey anti-
sheep (1:1000, Thermo Fisher Scientific, USA). Nuclei were stained with 4',6-diamidino-2-
phenylindole (DAPI, 1:100, Sigma-Aldrich, Australia). Sections were washed again 4 times 
for 15 mins and cover-slipped using Dako Fluorescence Mounting Medium (Dako, USA). 
 
2.6 Microscopy and quantitative analysis 
All images were acquired using a Diskovery spinning disk module with an inverted 
spinning disk. Images were captured and stitched using NIS software (Nikon Inc.). Images 
of the entire midbrain for E11 embryos and the ventral midbrain (vMB) for E14 embryos 
were captured using a 60x oil N.A. 1.4 objective (CFI Apo Lamda /W.D. 0.14mm), with an 
exposure time of 700ms for each channel (647, 568 and DAPI). Background was 
subtracted from the images using ImageJ (version 1.51, National Institutes of Health, 
USA), which was also used to crop and rotate the images. The images were then analysed 
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using a CellProfiler (version 3.0.0, Broad Institute, USA) pipeline developed by my co-
supervisor Dr. Wei Luan and Luke Hammond (Appendix 4). Background fluorescence 
thresholds were manually established to selectively identify Lmx1a and Sox2 nuclei. 
Protein expression was measured as the mean fluorescent intensity of Lmx1a and Sox2 in 
individual cells, which corresponded to the average grey value. Other measurements 
obtained included cell number, nuclear area, eccentricity and cell position.  
 
To verify the detection accuracy and correct segmentation of the CellProfiler pipeline (the 
percentage of correctly identified and segmented cells according to a human observer), 
Lmx1a+ and Sox2+ nuclei were manually counted in randomly selected regions (500 x 
500 pixels) in ROIs, and compared to the automated segmentation. Accuracy was 
calculated as the number of correctly identified and rejected objects (true positive) x 100 / 
true positive + false negative + false positive + over segmented objects + under 
segmented objects. Correct segmentation was calculated as the number of correct objects 
x 100 / correct objects + over segmented objects + under segmented objects. Images from 
42 embryos (3 sections/images per embryo, 126 images in total) were used (Appendix 5). 
 
Dividing cells were manually counted for each E11 image. DAPI staining was used as a 
reference, as shown in the image below (Fig. 1); cells were judged to be dividing if they 
were losing nuclear integrity (prophase to metaphase) or when the cell was separating and 
two daughter cells were visible (anaphase to telophase). If the cell was in anaphase or 
telophase, the spindle angle was manually measured in ImageJ. If the spindle angle is 
between 0-30º (horizontal division) or 30-60º (oblique division), this is considered 
asymmetric, neurogenic division, while 60-90º (vertical division) corresponds to symmetric, 
proliferative division (Chenn and McConnell, 1995). 
 
 
Fig. 1: MCF-cells stained with DAPI in the various stages of mitosis (He, 2006) 
 
2.7 Statistical analysis 
All data was analysed blind to treatment group, using a two-way repeated measures 
ANOVA. Statistical significance was set at p < 0.05. All statistical analyses were performed 
using SPSS software (version 23, SPSS Inc.). 
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Chapter 3: Results 
 
Using the CellProfiler pipeline, two populations of cells were investigated: progenitors, 
which were Lmx1a+ Sox2+ and postmitotic cells, which were Lmx1a+ Sox2-. For both E11 
and E14 embryos, we measured the following: cell number, Lmx1a expression, nuclear 
area and shape, and lateral and dorsoventral position. Additionally, Sox2 expression was 
measured and no significant differences were found between groups at either age 
(Appendix 6). At E11, dividing cells were manually counted and spindle angles were 
measured; this was not conducted at E14 as there were very few dividing cells at this 
stage. All non-significant statistical results are included in Appendix 6. 
 
3.1 E11  
  
A representative coronal section of an E11 embryo is shown below (Fig. 2). For each 
measurement obtained, data was analysed as the mean for each section along the 
anterior-posterior (A-P) axis.  
 
 
 
 
 
 
 
 
 
 
 
 
3.1.1 Accuracy of CellProfiler pipeline 
 
The average accuracy and correct segmentation was calculated for Lmx1a+ Sox2+ and 
Lmx1a+ Sox2- cells, as shown in the table below: 
 
Mean ± SD Lmx1a+ Sox2+ Lmx1a+ Sox2- 
Accuracy (%) 79.42 ± 10.75 77.09 ± 11.71 
Correct segmentation (%) 77.17 ± 11.53 76.27 ± 13.74 
VZ 
Sox2 
Lmx1a 
Lmx1a/Sox2 IZ+MZ 
Fig. 2: Lmx1a/Sox2 expression in a posterior coronal midbrain section from an E11 mouse 
embryo; VZ: ventricular zone, IZ: intermediate zone, MZ: mantle zone. 
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3.1.2 Cell number 
 
There were more progenitors than postmitotic cells, which was expected at this early age. 
In the progenitor population, there was a main effect of poly(I:C) treatment; poly(I:C) 
reduced the number of progenitors relative to the control groups, in the presence of both 
vehicle and vitamin D (two-way repeated measures ANOVA; F1,33=4.601, p=0.039; Fig. 
3a). There were no differences observed in the postmitotic cell population (Fig. 3b).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Fig. 3: Number of dopamine progenitors and postmitotic cells at E11. a Poly(I:C) reduced the 
number of progenitors in both VEH and VITD groups (main effect by two-way repeated 
measures ANOVA). b No differences in the number of postmitotic cells between groups were 
observed (POL-VEH, n=9; CON-VITD, n=10; CON-VEH, n=12; POL-VITD, n=11; data are 
shown as mean ± SEM; statistical significance indicated by *p < 0.05).  
 
a 
b 
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3.1.3 Lmx1a expression 
 
In the progenitor population, a main effect of vitamin D was observed (two-way repeated 
measures ANOVA; F1,31=5.688, p=0.023); post-hoc analysis revealed that there was a 
difference between the POL-VITD and POL-VEH groups, with vitamin D increasing Lmx1a 
expression in the presence of poly(I:C) (LSD post-hoc; p=0.019; Fig. 4a). There were no 
differences in Lmx1a expression in postmitotic cells (Fig. 4b). 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
Fig. 4: Lmx1a expression in progenitors and postmitotic cells at E11, measured as mean 
fluorescent intensity. a Vitamin D increased the expression of Lmx1a in the progenitors, in the 
POL group but not the CON group. b No differences in Lmx1a expression between groups 
were observed in the postmitotic cells (POL-VEH, n=9; CON-VITD, n=10; CON-VEH, n=12; 
POL-VITD, n=11; data are shown as mean ± SEM; statistical significance by LSD post hoc 
after significant main effect by two-way repeated measures ANOVA indicated by *p < 0.05). 
a 
b 
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3.1.4 Nuclear area 
 
In general, progenitor nuclear area was larger than that observed in postmitotic cells which 
is line with the fact that progenitors would be in the process of dividing. There were no 
significant effects of either maternal exposure observed between groups in either 
population of cells (Fig. 5). 
 
 
 
  
Fig. 5: Nuclear area of progenitors and postmitotic cells at E11. a No differences in area between 
groups were observed in progenitors. b No differences in area between groups were observed in 
the postmitotic cells (POL-VEH, n=9; CON-VITD, n=10; CON-VEH, n=12; POL-VITD, n=11; data 
are shown as mean ± SEM).  
 
a 
b 
 20 
3.1.5 Nuclear shape 
 
There was a main effect of poly(I:C) on nuclear shape, as measured by eccentricity 
(degree of deviation from being circular, circle = 0), in the progenitor population (two-way 
repeated measures ANOVA; F1,31=6.780, p=0.014); post-hoc analysis showed there was a 
difference between CON-VEH and POL-VEH, with poly(I:C) increasing eccentricity relative 
to controls (LSD post-hoc; p=0.012; Fig. 6a). No significant differences were observed in 
the postmitotic cells (Fig. 6b). 
 
 
 
 
 
 
 
 
  
Fig. 6: Nuclear shape as measured by eccentricity at E11. a Poly(I:C) increased the eccentricity 
of progenitors relative to controls. b No differences in nuclear shape between groups were 
observed in the postmitotic cells (POL-VEH, n=9; CON-VITD, n=10; CON-VEH, n=12; POL-VITD, 
n=11; data are shown as mean ± SEM; statistical significance by LSD post hoc after significant 
main effect by two-way repeated measures ANOVA indicated by *p < 0.05).  
 
a 
b 
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3.1.6 Lateral position 
 
There were no significant differences in lateral position relative to the midline in the 
progenitor population (Fig. 7a). There was a main effect of vitamin D in postmitotic cells 
(two-way repeated measures ANOVA; F1,31=6.968, p=0.013); post-hoc analysis revealed a 
significant difference between POL-VEH and POL-VITD, with vitamin D reducing lateral 
positioning in the poly(I:C) group (LSD post-hoc; p=0.042; Fig. 7b). 
 
 
  
Fig. 7: Lateral distance relative to midline at E11. a No differences in lateral distance between 
groups were observed in the progenitors. b Vitamin D reduced the lateral distance in the POL 
group in postmitotic cells (POL-VEH, n=9; CON-VITD, n=10; CON-VEH, n=12; POL-VITD, 
n=11; data are shown as mean ± SEM; statistical significance by LSD post hoc after 
significant main effect by two-way repeated measures ANOVA indicated by *p < 0.05).  
 
a 
b 
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3.1.7 Dorsoventral position 
 
Dorsoventral position refers to distance from the bottom of the mesencephalic aqueduct. 
There were no significant effects of maternal treatments on dorsoventral position observed 
between groups in either population of cells (Fig. 8). 
  
a 
b 
Fig. 8: Dorsoventral distance from the bottom of the mesencephalic aqueduct at E11. a No 
differences in dorsoventral position between groups were observed in progenitors. b No 
differences in dorsoventral position between groups were observed in the postmitotic cells 
(POL-VEH, n=9; CON-VITD, n=10; CON-VEH, n=12; POL-VITD, n=11; data are shown as 
mean ± SEM).  
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3.1.8 Dividing cells 
 
The number of dividing cells were manually counted for each section. There was a main 
effect of vitamin D treatment; vitamin D increased the number of dividing cells in both the 
control and poly(I:C) groups (two-way repeated measures ANOVA; F1,33=7.298, p=0.011; 
Fig. 9a). The same effect was seen when the total number of dividing cells per brain was 
analysed using a two-way ANOVA (F1,38=5.204, p=0.028; Fig. 9b). Post-hoc analysis 
showed that there was a difference approaching significance between POL-VEH and POL-
VITD (LSD post-hoc; p=0.054).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 9: Number of dividing cells at E11. a When the data was analysed per section, Vitamin D 
increased the number of dividing cells in both VEH and VITD groups (main effect by repeated 
measures two-way ANOVA). b The same effect was seen when the data was analysed as total 
number of dividing cells per brain (main effect by two-way ANOVA; POL-VEH, n=9; CON-VITD, 
n=10; CON-VEH, n=12; POL-VITD, n=11; data are shown as mean ± SEM; statistical 
significance indicated by *p < 0.05). 
a 
b 
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The spindle angle of cells in anaphase or telophase was also measured and no significant 
differences were found between groups, with the mean spindle angle for each group 
ranging between 78-82 degrees (Fig. 10a). For each group, over 90% of cells were 
undergoing vertical cleavage which would result in symmetric, proliferative division (Fig. 
10b).  
 
  
90° 
60° 
30° 
0° 
96.7% 
96.2% 
93.8% 
100% 
3.3% 
3.8% 
6.3% 
horizontal 
oblique 
vertical 
Fig. 10: Spindle orientation of dividing cells at E11. a There were no differences in mean spindle 
angle between groups. b Most cells were undergoing vertical cleavage, with a small percentage 
undergoing oblique cleavage (POL-VEH, n=9; CON-VITD, n=10; CON-VEH, n=12; POL-VITD, 
n=11; data are shown as mean ± SEM).  
a 
b 
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3.2 E14 
 
For the E14 images, we examined the same parameters used for E11 and conducted the 
analysis in the same way. As shown in Fig. 11, there is a notably reduced ventricular zone 
and expanded intermediate and mantle zone compared to E11; this reflects the end 
stages of mDA neurogenesis, with few remaining progenitors and a large population of 
postmitotic cells. The results for the E14 embryos can be summarised briefly, in that no 
significant effects of either maternal exposure were found for any of the measurements for 
either progenitors or postmitotic cells. A summary of the statistics is provided in Appendix 
6. 
 
  
VZ 
IZ 
MZ 
Sox2 
Lmx1a 
Lmx1a/Sox2 
Fig. 11: Lmx1a/Sox2 expression in an anterior coronal midbrain section from an E14 mouse 
embryo; VZ: ventricular zone, IZ: intermediate zone, MZ: mantle zone. 
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3.2.1 Cell number 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 12: Number of dopamine progenitors and postmitotic cells at E14. a No differences in 
the number of progenitors between groups were observed. b No differences in the number 
of postmitotic cells between groups were observed (POL-VEH, n=8; CON-VITD, n=6; CON-
VEH, n=9; POL-VITD, n=11; data are shown as mean ± SEM).  
 
a 
b 
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3.2.2 Lmx1a expression  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 13: Lmx1a expression in progenitors and postmitotic cells at E14, measured as 
mean fluorescent intensity. a No differences in Lmx1a expression between groups 
were observed in progenitors. b No differences in Lmx1a expression between groups 
were observed in postmitotic cells (POL-VEH, n=8; CON-VITD, n=6; CON-VEH, n=9; 
POL-VITD, n=11; data are shown as mean ± SEM). 
 
a 
b 
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3.2.3 Nuclear area 
 
 
  
a 
b 
Fig. 14: Nuclear area of progenitors and postmitotic cells at E14. a No differences in 
area between groups were observed in progenitors. b No differences in area between 
groups were observed in postmitotic cells (POL-VEH, n=8; CON-VITD, n=6; CON-VEH, 
n=9; POL-VITD, n=11; data are shown as mean ± SEM). 
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3.2.4 Nuclear shape 
  
a 
b 
Fig. 15: Nuclear shape as measured by eccentricity at E14. a No differences in shape 
between groups were observed in progenitors. b No differences in shape between groups 
were observed in postmitotic cells (POL-VEH, n=8; CON-VITD, n=6; CON-VEH, n=9; 
POL-VITD, n=11; data are shown as mean ± SEM). 
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3.2.5 Lateral position 
 
  
a 
b 
Fig. 16: Lateral distance relative to midline at E14. a No differences in lateral distance 
between groups were observed in progenitors. b No differences in lateral distance between 
groups were observed in postmitotic cells (POL-VEH, n=8; CON-VITD, n=6; CON-VEH, 
n=9; POL-VITD, n=11; data are shown as mean ± SEM). 
 
 31 
3.2.6 Dorsoventral position 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a 
b 
Fig. 17: Dorsoventral distance from the bottom of the mesencephalic aqueduct at E14. 
a No differences in dorsoventral position between groups were observed in 
progenitors. b No differences in dorsoventral position between groups were observed 
in postmitotic cells (POL-VEH, n=8; CON-VITD, n=6; CON-VEH, n=9; POL-VITD, 
n=11; data are shown as mean ± SEM). 
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Chapter 4: Discussion  
 
Overall, we have observed subtle effects of poly(I:C) on early DA development at E11, 
with vitamin D having some neuroprotective effects. Poly(I:C) reduced the number of mDA 
progenitors and altered progenitor nuclear shape, while vitamin D increased Lmx1a 
expression in progenitors and reduced the lateral distance of postmitotic cells in poly(I:C)-
treated animals. Additionally, vitamin D increased the number of dividing cells in both 
poly(I:C) and control groups. By E14, no effects of treatment were observed, suggesting 
that the alterations in Lmx1a+ cells observed at E11 were transient. 
 
4.1 Progenitor proliferation and mDA neuron migration 
 
My results suggest that both poly(I:C) and vitamin D can impact mDA progenitor 
proliferation. Poly(I:C) was shown to reduce the number of progenitors at E11, in both 
vehicle and vitamin D-treated animals. This suggests that poly(I:C) may be acting to inhibit 
progenitor proliferation in the developing vMB. Previous studies in other cell types have 
demonstrated similar effects of poly(I:C), acting specifically through TLR3. Poly(I:C) was 
found to reduce proliferating cells (labelled with BrdU) in embryonic cortical neurospheres 
derived from wild-type but not TLR3 knock-out mice (Lathia et al., 2008). Interestingly, they 
showed that TLR3 was present in Sox2+ cells and strongly expressed at E12.5, a period 
when cortical neural progenitor cells (NPCs) are highly proliferative, and steadily 
decreased as the progenitor pool diminished. It is possible that the poly(I:C)-induced 
inhibition of progenitor proliferation is mediated by cytokines downstream of TLR3 
signalling. As thoroughly outlined by Borsini et al., cytokines including IL-1β, IL-6 and IFNs 
have been shown to reduce NPC proliferation (Borsini et al., 2015). For example, IL-1β 
has been shown to inhibit the proliferation of NPCs derived specifically from E14 rat vMB 
by promoting differentiation towards a glial lineage (Crampton et al., 2012). It is important 
to keep in mind that these cytokines can have different effects depending on 
concentration, brain region, cell type and stage of neurodevelopment (Meyer, 2013).  
 
Additionally, we have demonstrated that poly(I:C) increased progenitor eccentricity relative 
to controls. The eccentricity of a circle is zero, so an increase in eccentricity 
indicates that a cell is more elongated. This is supportive of poly(I:C) affecting cell division, 
which is one of the main reasons for cells to be changing shape, with cells becoming 
 33 
round when they enter M-phase and elongating during anaphase (Clark and Paluch, 
2011). 
 
Following on from this, we did not observe any effects of poly(I:C) on the number of 
dividing cells, which was actually increased by vitamin D in both control and poly(I:C)-
treated animals. Examination of spindle angle revealed that most cells were undergoing 
symmetric, proliferative division, which would expand the progenitor pool, as opposed to 
asymmetric, neurogenic division (Götz and Huttner, 2005). This contrasts with the 
literature as vitamin D typically exhibits anti-proliferative, pro-differentiating effects in  
neuronal cells (Cui et al., 2017). Vitamin D has been found to reduce neurosphere 
production from neonatal subventricular zone (SVZ) cultures and inhibit mitosis in 
embryonic hippocampal cells, possibly by altering the expression of cell cycle regulatory 
proteins (Brown et al., 2003; Cui et al., 2007). In line with this, DVD deficiency results in 
increased proliferation across multiple brain regions from E19 onwards (Eyles et al., 2003; 
Ko et al., 2004). This contradiction with my results could have several explanations. Firstly, 
these previous studies reporting on proliferation have used either BrdU or PCNA, which 
are well-established molecular markers of proliferating cells. In this study, I manually 
counted dividing cells based on various mitotic criteria, using DAPI staining as a reference. 
This is quite a subjective method and results could differ depending on the observer. 
Secondly, the effect of vitamin D could vary depending on brain region and age, as 
previous studies have not examined proliferation this early in brain development and never 
specifically in the vMB. Two experiments are required to confirm my finding. First, a more 
definitive method of measuring proliferation needs to be employed, such as BrdU labelling. 
Second, cell division needs to be assessed in additional regions to establish whether the 
finding of vitamin D increasing cell division is selective for the midbrain.  
 
We also showed that vitamin D reduced the lateral position of postmitotic mDA neurons in 
poly(I:C)-treated animals. This likely reflects altered migration, with poly(I:C) increasing 
migration away from the midline and vitamin D counteracting this effect. At E11, mDA 
neurons have just begun differentiating and are still largely located in the ventricular zone 
(Blaess and Ang, 2015). They initially undergo radial migration to the mantle layer, after 
which neurons destined for the SN migrate tangentially to their final position from around 
E12.5 (Bodea et al., 2014). If neurons have moved further in poly(I:C)-treated animals, this 
could correspond with cells being at a later stage of differentiation. Without Nurr1/TH 
staining, however, it is difficult to comment on the differentiation status of these neurons 
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(this will be further discussed in section 4.3). Alternatively, this could reflect a tangential 
migration abnormality. There are several proteins thought to be involved in mDA neuron 
tangential migration; these include the cell adhesion molecule L1CAM, its potential ligand 
PTPRZ1, the extracellular matrix molecule REELIN and its downstream effector DAB1 
(Blaess and Ang, 2015). Alterations in these proteins have been shown to result in 
abnormal mDA neuron positioning; for example, L1CAM knock-out mice demonstrate an 
altered rostrocaudal distribution of DA neurons, while in REELIN deficient mice, neurons 
destined for the SN fail to migrate laterally and accumulate anomalously in the VTA area 
(Demyanenko et al., 2001; Nishikawa et al., 2003). Examining the location of Nurr1+/TH+ 
neurons in older embryos will shed light on the potential effect of poly(I:C) on tangential 
migration.   
 
4.2 Vitamin D and Lmx1a 
 
We observed that vitamin D increased progenitor Lmx1a expression in poly(I:C)-treated 
animals. Expression was measured as mean fluorescent intensity per individual cell, so 
this would reflect an increase in actual cell content rather than an increase in cell number. 
Vitamin D could be influencing Lmx1a expression by interacting with signalling pathways 
involved in regulating this protein. As described earlier, the Wnt pathway directly regulates 
the expression of Lmx1a through the transcriptional co-activator β-catenin (Chung et al., 
2009). Vitamin D has been shown to upregulate Wnt signalling in osteoblasts by 
enhancing the expression of Lrp5, a co-receptor in the Wnt pathway involved in stabilising 
β-catenin (Fretz et al., 2007). This is mediated by the hormone-bound VDR binding to a 
specific vitamin D response element (VDRE) within the Lrp5 gene locus. In contrast, 
studies in other cell types have found that vitamin D can inhibit Wnt signalling. This has 
largely been demonstrated in colon cancer cells, where vitamin D acts through several 
mechanisms, including VDR binding to and preventing β-catenin activity and the induction 
of Wnt pathway antagonisers (Larriba et al., 2013). It is important to note that in the 
context of cancer cells, the Wnt pathway is abnormally activated, which could alter its 
interplay with vitamin D signalling. This is exemplified by vitamin D inhibiting β-catenin in 
osteosarcoma cells, in contrast to its stimulation of the Wnt pathway in normal bone 
formation (H. Yang et al., 2011). Another possible mediator between vitamin D and β-
catenin is N-cadherin; vitamin D increases N-cadherin in vitro, and N-cadherin has been 
shown to regulate β-catenin activity in the vMB (Sakane and Miyamoto, 2013; Cui et al., 
2015). The relationship between vitamin D and Wnt signalling in neurons has yet to be 
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examined but would be an interesting area of investigation, particularly during embryonic 
development where Wnt signalling is in involved in fundamental ontogenetic processes.  
 
Lmx1a expression is also influenced by the Shh-FoxA2 pathway. Shh expressed in the 
notochord induces FoxA2 expression in the vMB through the downstream effector Gli, and 
FoxA2 in turn acts as a feedback regulator to modulate Shh signalling (Chung et al., 2009; 
Metzakopian et al., 2012). FoxA2 is involved in maintaining Lmx1a expression and also 
functions cooperatively with Lmx1a to coordinate mDA specification (Lin et al., 2009; 
Nakatani et al., 2010). Interestingly, a reduction in fetal brain Shh expression has been 
demonstrated in the poly(I:C) model (Meyer et al., 2008). Vitamin D has been shown to 
inhibit Shh signalling in various cancer cell types, possibly by negatively regulating the 
downstream protein Smoothened (SMO) (Uhmann et al., 2011, 2012; Linder et al., 2015). 
As with the Wnt pathway, interactions between vitamin D and Shh have not yet been 
demonstrated in neurons; if vitamin D is playing a similarly reversed role in non-cancerous 
tissues as observed with Wnt, it is possible that upregulating Shh in deficient poly(I:C)-
treated animals could lead to a subsequent increase in Lmx1a expression. In order to 
investigate the effect of vitamin D on Wnt and Shh signalling, in vitro studies could be 
done looking at possible interactions between vitamin D/VDR and components of these 
signalling pathways. For example, our lab often utilises chromatin immunoprecipitation 
(ChIP) assays in a cell-line transfected with VDR to investigate the effect of vitamin D on 
VDR binding to particular genes of interest (Pertile et al., 2016, 2017). It is important to 
keep in mind that a delicate antagonistic balance between Wnt and Shh signalling is 
required for the correct progression of mDA progenitors to neurons, such that an 
appropriate amount of activation and inhibition of both pathways are required at specific 
temporal intervals (Joksimovic et al., 2009; Tang et al., 2010). 
 
4.3 Lmx1a in DA development 
 
Given these alterations in early DA ontogeny, which were mostly observed in Lmx1a+ 
progenitors, it is important to think about the roles that Lmx1a plays and the potential 
consequences on the developing brain. Downstream of Lmx1a, a cascade of transcription 
factors are activated which orchestrate DA neurogenesis. Firstly, Lmx1a induces the 
expression of msh homeobox 1 (Msx1), which then goes on to induce the proneural gene 
neurogenin 2 (Ngn2), thus initiating neural differentiation (Andersson et al., 2006). 
Overexpression of Lmx1a in the chick vMB results in the ectopic expression of DA 
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neurons, while silencing Lmx1a expression results in a dramatic reduction in DA neurons 
(Andersson et al., 2006). Analysis of dreher mice, which carry a hypomorphic mutation in 
the Lmx1a locus, has shown that Lmx1a alone is not sufficient for progenitor specification 
and there is a less severe reduction in the generation of DA neurons (Ono et al., 2007). In 
mice with a null mutation of Lmx1a, there is an initial loss of DA neurons at E11.5 
accompanied by the loss of Ngn2 expression and prolonged Shh expression in the ventral 
midline, suggesting delayed neurogenesis and the maintenance of FP-properties (Deng et 
al., 2011). Although neurogenesis mostly recovers in these mutants, there is a modest 
reduction of DA neurons at early postnatal stages in the VTA. The authors of this study 
also examined the role of the related protein Lmx1b, which is more broadly expressed in 
the midbrain at early developmental stages. Their data suggests that the combined activity 
of both LIM proteins is required for the generation of DA neurons, describing a 
heterogeneous DA progenitor domain with distinct medial and lateral subpopulations, of 
which DA specification relies on Lmx1a and Lmx1b respectively.  
 
In a study by Yan et al., the cooperative functions of Lmx1a/b were further demonstrated 
in double mutant mice, where a severe loss of DA neurons was observed (Yan et al., 
2011). The authors examined DA progenitors, immature and mature neurons and found 
the whole population to be reduced at E12.5, with the reduction in mature neurons 
persisting to E18.5. Further analysis revealed that the reduction in progenitors was caused 
by a decrease in proliferation and increase in cell cycle exit, with Lmx1a/b regulating the 
expression of Wnt1 and key cell cycle proteins. The remaining progenitors in the double 
mutants were not fully specified, failing to express Msx1, with a subsequent loss of Ngn2 
correlating with neurogenesis defects. Lmx1a/b were also required for specifying 
postmitotic DA neurons by repressing Lim1/2, which are normally expressed in red 
nucleus neurons. Overall, these studies highlight the importance of Lmx1a in the 
specification, proliferation and differentiation of DA progenitors.  
 
This crucial role of Lmx1a during initial periods of DA development fits in with my results, 
where I observed changes in Lmx1a+ cells at E11, the peak of mDA progenitor 
proliferation. If MIA is disrupting DA ontogeny at this developmental stage, Lmx1a would 
invariably be affected. Subsequently, by E14, DA neurogenesis is almost complete and 
most progenitors have differentiated; Lmx1a continues to be expressed but no longer 
plays such a critical role (Arenas et al., 2015). It is therefore not surprising that we did not 
observe changes in Lmx1a+ cells at this age; if MIA continues to have effects at E14, this 
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will most likely be reflected in the postmitotic lineage markers, Nurr1 and TH, which will be 
discussed further in section 4.6.  
 
Perhaps the most notable effect of poly(I:C) at E11 was the reduced number of 
progenitors. It is possible that MIA might be inducing precocious differentiation, which 
could underlie the increased lateral position of postmitotic cells also observed at E11. By 
E14, there are no changes in the number of progenitors or postmitotic cells; however, 
analysis of Nurr1 and TH would reveal possible changes in the number of immature and 
mature DA neurons resulting from any early alterations in differentiation. While this 
proposition may not be in line with the reduction in Nurr1 observed at E11 in the poly(I:C) 
model and subsequent normalisation at E13, it could potentially relate to the increased 
number of DA neurons observed at E17 and E19 (Meyer et al., 2008; Vuillermot et al., 
2010). Also, it is important to note that the previous measurements of Nurr1 were made in 
whole brains, rather than the vMB specifically. Previous studies looking at the effects of 
poly(I:C) on endothelial progenitor cells (EPCs) also found proliferation to be inhibited, 
mediated in part by the downregulation of cyclins leading to cell cycle arrest (Yang et al., 
2011). The differentiation of neural progenitor cells is preceded by an extended G1 phase 
and cell cycle exit, which is associated with the decreased activity of cyclins (Lange and 
Calegari, 2010; Hardwick et al., 2015). Additionally, poly(I:C) was shown to induce 
apoptosis in EPCs, which has also been demonstrated in several cancer cell types (Nomi 
et al., 2010; Harashima et al., 2014). Apoptosis could therefore be another possible 
explanation for the reduction in progenitors observed in this study; this could be 
investigated in the future using flow cytometry with Annexin V/propidium iodide staining.  
 
While vitamin D did not rescue the reduction in progenitor cell number at E11, it did 
increase Lmx1a expression when co-administered with poly(I:C). Perhaps, if poly(I:C) was 
inducing cell cycle exit and hence early differentiation, vitamin D could be acting to 
counteract this by upregulating Lmx1a in order to maintain progenitor proliferation. This 
could even relate to the enhanced cell division induced by vitamin D in progenitors. On the 
one hand, vitamin D has prominent anti-proliferative effects as mentioned earlier, 
particularly in the context of cancer cells, which is thought to be a result of cell cycle 
inhibition (Spina et al., 2006). However, vitamin D has been shown to promote proliferation 
in some cell types by upregulating factors involved in cell-specific proliferation; for 
example, 1,25OHD enhances the proliferation of hematopoietic stem and progenitor cells 
by increasing the expression of the chemokine CXCL8, and stimulates EPC proliferation 
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by upregulating vascular endothelial growth factor (Ng et al., 2011; Grundmann et al., 
2012; Cortes et al., 2016).  
 
Overall, the results offer some support towards my hypothesis; firstly, poly(I:C) impaired 
mDA progenitor proliferation, however, this was not due to reduced Lmx1a expression. 
Rather, this may have been a result of early differentiation, which could have induced 
aberrant lateral migration. Vitamin D did have some neuroprotective effects as 
hypothesised, i.e. increasing Lmx1a expression, which may have contributed to 
maintaining progenitor proliferation, as well as normalising lateral migration. These ideas 
are summarised in Fig. 18. On the whole, we did not observe particularly dramatic 
changes in Lmx1a+ cells at E11 or E14, which could indicate that the more pronounced 
effects of MIA and neuroprotective properties of vitamin D are occurring downstream of DA 
progenitor specification and proliferation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 18: Summary of findings in relation to mDA progenitor proliferation. Poly(I:C) could 
be inhibiting proliferation by inducing early differentiation, resulting in increased lateral 
migration. Vitamin D may be maintaining proliferation by upregulating Lmx1a, resulting 
in more dividing cells and reduced lateral migration.  
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4.4 Spatiotemporal dynamics of DA development 
 
As illustrated by the cooperative functions of Lmx1a and Lmx1b described earlier, the 
transcription factors governing DA development do not function independently; rather, they 
form part of a complex genetic network. Dissecting the underlying molecular circuitry has 
predominantly been achieved through genetic studies, including loss and gain of function, 
conditional gene inactivation and genetic fate-mapping (Blaess and Ang, 2015). The 
quantitative immunohistochemistry techniques utilised in this project have allowed us to 
delve further into details of mDA neuron anatomy. While these results do not inform us 
about gene and protein interactions, they do show interesting patterns in terms of anterior-
posterior axis differences. Early studies using [3H]thymidine autoradiography to birthdate 
neurons established that neurons in the SN are born earlier than those in the VTA, with an 
anterior (early) to posterior (late) gradient of neurogenesis (Bayer et al., 1995). Here we 
see an abundance of posterior progenitors at E11, which is still maintained at E14, 
accompanied by few posterior postmitotic neurons; these progenitors are likely to become 
the later-generated VTA neurons. In contrast, anterior neurons have already started 
differentiating at E11 and become more abundant at E14, corresponding to early-
generated SN neurons. This also fits in with the patterns we observed in lateral and 
dorsoventral positioning, which were more pronounced at E14 compared to E11. As 
mentioned earlier, this relates to DA neuron migration, with radial migration out of the 
ventricular zone occurring around E12.5-E13.5 (Bodea et al., 2014). Once these neurons 
have reached the mantle layer, those destined for the SN undergo tangential migration; 
congruently, we observed neurons in anterior sections located ventrally and further 
laterally than neurons in posterior sections. 
 
Exemplified by these findings, one of the striking advantages of our techniques in studying 
DA development is spatial resolution. We are able to measure cell number, protein 
expression, spatial position and nuclear shape and size along the anterior-posterior axis, 
as well as in specific subsets of cells. This allows for the refinement of more generalised 
gross findings. For example, our lab found Nurr1 mRNA to be reduced in the midbrain of 
DVD embryos using real-time PCR; this finding was then extended using similar 
techniques to those used in this project, where Nurr1 expression was shown to be reduced 
specifically in immature and mature DA neurons in the VTA but not SN. These results 
point towards the diversity of DA neurons, wherein SN and VTA neurons are not only 
functionally but developmentally distinct; they are generated from different progenitor 
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subgroups, with distinct spatiotemporal gene expression governing specification and 
differentiation (Bodea and Blaess, 2015). It is consequently not surprising that an 
environmental perturbation would have a regionally heterogeneous effect on the 
expression of a particular gene. Our techniques could be applied more generally to better 
understand mDA neuron subtypes; for example, delineating where proteins are expressed 
in subpopulations of mDA progenitors and whether gradients of expression exist.  
 
4.5 Technical limitations  
 
As with any technique, our methods have several limitations. Firstly, there was 
considerable variation in the protein expression data, particularly at E11, whereas the 
variation in the other parameters measured was much tighter (see Appendix 1). Since 
expression was measured using fluorescent intensity, this variation could be a result of 
inconsistent staining between slides. Each slide contained sections from one embryo, so 
with six embryos per experimental group, there was a total of 48 slides. We stained all of 
the slides in the same batch in order to exclude batch-to-batch variation. However, even 
within one batch, the slides were not processed simultaneously; applying the antibodies 
and mounting the slides spanned two to three hours. On top of this, imaging took between 
11-14 days, during which some photobleaching could occur. Additionally, if there was a 
problem with one particular slide, for example, if sections were damaged during mounting, 
this meant that a whole embryo had to be excluded.  
 
Another factor to consider is the accuracy rate of the CellProfiler pipeline, which was 
between 77-79%, while correct segmentation was between 76-77%. This means that 
around 20% of cells were incorrectly identified, which could also contribute to variance.  
Similar single cell detection and segmentation techniques, which are often used for 
histopathology, have accuracy values ranging from around 70-99% (Xing and Yang, 
2016). The challenges commonly encountered are heterogenous cell types and 
crowded/overlapping cells, alongside the fact that images of tissue sections contain 2D 
projections of 3D structures (Blom et al., 2017). One means of improving the accuracy, 
which could serve as a follow-up to validate the results of this project, would be to do 
conduct 3D image analysis. Such a method is described in Luan et al., 2017, using Imaris 
software, which yielded accuracy scores above 95% (Luan et al., 2017).  
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4.6 Future directions 
 
As mentioned earlier, the next step for this project is to complete the analysis of Nurr1 and 
TH at E11 and E14. The staining and imaging of Nurr1/TH for E11 embryos has been 
completed and the images have gone through the first stage of processing. However, I did 
not have enough time to complete this analysis in addition to the analysis of Lmx1a/Sox2 
at E14.  
 
If Nurr1 expression is reduced in the poly(I:C) model at E11 as previously observed, one of 
the neuroprotective effects of vitamin D might be to increase Nurr1. Vitamin D has been 
shown to upregulate Nurr1 in the adult rat hippocampus (Latimer et al., 2014). One 
possible mechanism could involve the 9-cis retinoic acid receptor RXR, which 
heterodimerises with both Nurr1 and the VDR (Yu et al., 1991; Vinh quôc Luong and Thi 
Hoàng Nguyên, 2012). The VDR/RXR complex induces the release of transcriptional co-
repressors such as NcoR2, which keep nuclear receptors in repressed states (Cui et al., 
2017). The dissociation of such co-repressors from Nurr1 promotes histone acetylation at 
the promoter region of DA genes, facilitating transcription (Blaess and Ang, 2015). These 
genes include TH, DA transporter (DAT), aromatic L-amino acid decarboxylase (AADC) 
and vesicular monoamine transporter 2 (VMAT-2), factors which define a mature DA 
neuron (Jankovic et al., 2005). Interestingly, both the DVD and poly(I:C) models show 
alterations in DAT, which could contribute to the increased amphetamine-induced 
locomotion also observed in both models (Kesby et al., 2010). Additionally, adult Nurr1 
heterozygous mice also display this behavioural deficit alongside other phenotypes 
relevant to schizophrenia, thus providing a direct link between this developmental 
transcription factor and postnatal abnormalities (Rojas et al., 2007).  
 
Another possible downstream target of vitamin D and Nurr1 is glial cell-line derived 
neurotrophic factor (GDNF), which is involved in the survival of DA neurons (Arenas et al., 
2015). In animal models of Parkinson’s disease, administration of vitamin D increases 
GDNF expression and protects against DA neuron loss (Smith et al., 2006; Sanchez et al., 
2009). As a point of convergence, both Nurr1 and vitamin D have been shown to regulate 
the expression of the GDNF receptor c-ret (Decressac et al., 2012; Pertile et al., 2017). 
Furthermore, Nurr1 has a well-established role in regulating the transcription of TH and 
vitamin D has been shown to directly modulate TH expression in vitro (Sakurada et al., 
1999; Cui et al., 2015; Pertile et al., 2016).  
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If there are no changes in Nurr1 and TH at E11 or E14, it is possible that MIA and vitamin 
D are having effects at later developmental stages. This project has focussed on early 
aspects of DA development, from mDA progenitor proliferation to the final stages of 
differentiation. From E14 onwards, DA neurons migrate to their final positions and extend 
their axons towards their target areas, innervating the striatum and the cortex (Hegarty et 
al., 2013). It is possible that MIA is impairing one of these later aspects of circuit formation, 
with downstream effects on DA connectivity. Alternatively, there could be adverse effects 
on other factors involved in DA ontogeny which we did not examine; for example Pitx3 is 
another transcription factor involved in the terminal differentiation and survival of DA 
neurons and is also reduced in poly(I:C)-treated embryos (Meyer et al., 2008). Finally, it is 
possible that our hypothesis is wrong and the neuroprotective effects of vitamin D in the 
MIA model are not occurring within the dopaminergic system. For example, MIA offspring 
display alterations in other neurotransmitter systems relevant to schizophrenia, including 
glutamate and GABA (Cassella et al., 2016; Pendyala et al., 2017). In order to prove or 
reject our hypothesis, a complete analysis of the entire DA lineage is required; this would 
encompass immature and mature DA neurons, along with later stages of development.  
 
In terms of the behavioural outcomes of vitamin D in the poly(I:C) model, there are several 
additional considerations. Firstly, the timing of maternal infection is a key determining 
factor in terms of both the cytokine response in the fetus and postnatal behavioural 
outcomes (Meyer et al., 2006). Importantly, DA-related functional impairments are critically 
influenced by timing and stages of development. Amphetamine hypersensitivity emerges 
during adulthood following early/middle and late poly(I:C) challenge; however, prepubertal 
sensitivity was only apparent following poly(I:C) during early/middle but not middle/late 
gestation (Ozawa et al., 2006; Meyer, Nyffeler, Yee, et al., 2008). PPI deficits, which are 
also modulated by dopaminergic mechanisms, only emerge in adults following 
early/middle but not late immune activation (Zhang et al., 2000; Meyer, Nyffeler, 
Schwendener, et al., 2008). Correspondingly, altered dopamine receptor expression in the 
striatum follows a similar postpubertal onset (Vuillermot et al., 2010). This points towards 
the dynamic nature of developmental DA abnormalities, which may interact with 
maturational processes to precipitate age-dependent outcomes. This is supported by the 
observation that changes in Nurr1 and TH expression are apparent during fetal and adult 
but not peripubertal stages (Vuillermot et al., 2010). Interestingly, vitamin D was able to 
rescue poly(I:C)-induced amphetamine hypersensitivity in both juveniles and adults but did 
not prevent PPI impairments (manuscript in preparation). Future studies could be 
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conducted investigating the role of MIA and vitamin D on factors involved in peripubertal 
maturation as well as structural DA-changes from adolescence into adulthood.  
 
For future developmental experiments, the breeding protocol employed in this project 
should be used as it greatly minimised experimental variance, compared to preliminary 
experiments using standard time-mating (Appendix 1). To examine variance, the ratio of 
postmitotic to progenitor cell number was calculated, as an indicator of an embryo’s stage 
of development – for example, older embryos would have a higher ratio as there would be 
more postmitotic cells. Variance would therefore be a result of having embryos at different 
stages of development, outside of the required age. Restricting the breeding window to 
three hours ensured that there were no outliers and less variance in embryo age.  
 
Another interesting finding which could be followed up is the effect of vitamin D on 
poly(I:C)-induced sickness behaviour, where vitamin D reduced the intensity of sickness 
behaviour in non-pregnant animals (Appendix 2). This suggests that vitamin D could be 
having an anti-inflammatory role in terms of immediate poly(I:C)-induced immune 
reactions. While vitamin D has been shown to have no effect on the levels of three 
poly(I:C)-induced cytokines, IL-1β, IL-6 and TNF-ɑ (Vuillermot et al., 2017), it would be 
interesting to investigate whether vitamin D is acting to downregulate additional cytokines 
such as type 1 IFNs, which have been implicated in the acute symptoms of viral infection 
(Cunningham et al., 2007). The differential responses between pregnant and non-pregnant 
animals likely relates to the hormone-mediated modulation of the immune system 
observed during pregnancy, which can lead to skewed inflammatory responses (Mor and 
Cardenas, 2010; Robinson and Klein, 2012).  
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4.7 Conclusions and significance  
 
In summary, we have demonstrated proximal, transient effects of maternal immune 
activation and vitamin D on early DA neuron development. In terms of the adverse effects 
of MIA, this was primarily the reduction of progenitors at E11; while this effect was not 
rescued by vitamin D, there were other neuroprotective actions in terms of Lmx1a 
expression and a normalisation of lateral positioning. By E14, no alterations in Lmx1a+ 
cells were observed. This time-limited effect echoes the transience of the acute maternal 
treatments, wherein both poly(I:C)-induced cytokines and vitamin D reach maximal levels 
within 6 hours post-administration and steadily decrease thereafter (Healy et al., 2003; 
Cunningham et al., 2007). These environmental factors do not induce static ‘one-off’ 
events, especially in the dynamic context of development. Rather, ontogenetic processes 
are disturbed which interfere with the correct progression of mDA progenitors to functional 
DA neurons. Once the dopaminergic system is compromised during development, later 
interactions with postnatal maturational processes, and perhaps further insults, could lead 
to the emergence of behavioural abnormalities.  
 
This work contributes to furthering our understanding of schizophrenia aetiology, 
particularly towards reconciling two of the major hypotheses about the disorder – its 
neurodevelopmental origins and the centrality of dopamine dysfunction. A thorough 
understanding of the underlying neurobiology of schizophrenia will advance the 
development of better, more comprehensive treatments, which address more than just one 
subset of symptoms. The findings from this project support the idea of different 
environmental risk factors converging on developing dopaminergic systems in a common 
pathway towards a disordered brain.  
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Appendices  
 
Appendix 1: Breeding protocol improved experimental variance 
 
In order to reduce the age differential observed in embryos obtained from standard time-
mated dams, we adopted a three-hour breeding window. To assess whether this reduced 
experimental variance, we examined the ratio of postmitotic to progenitor cell number 
obtained from Dr. Luan’s preliminary experiments vs. my experiments. A summary of 
statistics, per section, is shown in the table below, and mean ± standard deviation is 
illustrated in the graphs; overall, variance is substantially reduced in my data (yellow) 
compared to preliminary experiments (green). We also looked at the number of outliers in 
each set of data, as a more specific indicator of embryos that were at a different stage of 
development compared to the majority. Outliers were defined as data points outside of the 
higher range (= Q3 + 2.2 x IQR) and lower range (= Q1 - 2.2 x IQR), where Q1 is the first 
quartile, Q3 is the third quartile and IQR is the inter-quartile range (Q3 - Q1) (Hoaglin and 
Iglewicz, 1987). In the preliminary data, there were 4 outliers out of 40 embryos, while 
there were no outliers in the 42 embryos I analysed. 
 
 Sc1 Sc2 Sc3 Sc4 Sc5 Sc6 
Mean 
0.631 0.509 0.446 0.377 0.300 0.192 
0.834 0.691 0.601 0.440 0.320 0.199 
SD 
0.888 0.477 0.415 0.332 0.267 0.207 
0.260 0.209 0.254 0.190 0.129 0.124 
SEM 
0.140 0.075 0.066 0.053 0.042 0.033 
0.041 0.032 0.039 0.029 0.020 0.019 
Variance 
0.788 0.228 0.172 0.110 0.071 0.043 
0.068 0.044 0.065 0.036 0.017 0.015 
 
  
Sc; section 
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Appendix 2: Sickness behaviour  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Experimental/ Treatment Group: AEC Number: QBI/478/15
Name of person scoring: Name of Supervisor/Chief Investigator: Prof. Darryl Eyles
Contact Number: Contact Number: 33466370
Animal ID: GT# Weight: ___________________ gm
Injection volume: ___________________ µL
Post injection:
1h 2h 3h 4h 5h 6h 24h 48h
Date:
0 1 2 3          Time:
Activity normal
less grooming, 
abnormal 
posture
huddled, no 
activity fitting
Alertness normal
dull, slow to 
respond
minimal 
response to 
handling
unconscious
Breathing normal rapid shallow  
Coat normal rough
unkept, 
wounds, hair 
thinning
severe hairloss, 
bleeding wounds
Faecal 
formation
normal diarrhea
Movement normal
slight 
incoordination 
or abnormal 
gait
lethargic, 
reluctant to 
move
staggering, limb 
dragging or paralysis
For Total scores: ** A score of 3 in any 1 category = euthanase Signature of person scoring:
0 = Normal : no action
1-8 = Moderate changes: Monitor daily
8-15 = Significant changes : Monitor twice daily
≥15 = Euthanase
References
1. Morton, D.B. (1997). A scheme for the recognition and assessment of adverseeffects. In:Animal Alternatives, Welfare and Ethics. (Eds. LFM vanZutphen     and M. Balls).  ElsevierScience, Amsterdam. pp. 235-241.
Poly I:C sickness behaviour - Score sheet
Pre-injection 
Additional comments
3. Cunningham et al (2007), The sickness behaviour and CNS inflammatory mediator profile induced by systemic challenge of mice with synthetic double-stranded RNA (poly I:C), Brain, Behavior, and Immunity, Volume 21, Issue 4, May 2007, Pages 490-502
Total Score:
2. Morton, D.B. (1998). The use of score sheets in the implementation of humaneend points.Proceedings of the Joint ANZCCART / NAEAC Conference on EthicalApproaches to Animalbased Science (Eds. D. Mellor, M. Fisher and G.Sutherland), ANZCCART, Adelaide andWellington. pp: 75-82.
 III 
Sickness behaviour results: 
 
The sickness behaviour data was pooled from each breeding wave (of which there were 
two for E11 and two for E14). The total sickness score was calculated for each animal for 
every hour, and these scores were then averaged for each treatment group. I first 
analysed all females irrespective of pregnancy and then I looked at non-pregnant and 
pregnant animals separately.  
 
Poly(I:C) induced sickness behaviour within one-hour post injection, which peaked at 
around 3 hours, after which animals started recovering. When pregnant and non-pregnant 
animals were analysed together, there was a significant difference between POL-VEH and 
POL-VITD, with vitamin D reducing the sickness impact of poly(I:C) (Fig. 1). The same 
effect was seen when non-pregnant animals were analysed separately (Fig. 2), however, it 
was not observed in pregnant animals (Fig. 3).  
 
  
Fig. 1: Average sickness behaviour scores for all females following intravenous (IV) 
administration of poly(I:C) (POL) or saline solution (CON) and subcutaneous (SC) administration 
of 1,25OHD (VITD) or vehicle (VEH). There was a main effect of IV (F1,101=291.812, p<0.0001) 
and SC (F1,101=4.831, p=0.03). LSD post-hoc analysis showed significant differences between 
POL-VEH and CON-VEH as well as POL-VITD and CON-VITD (p<0.0001), in addition to POL-
VEH and POL-VITD (p=0.015). (POL-VEH, n=28; CON-VEH, n=27; POL-VITD, n=22; CON-VITD, 
n=28; data are shown as mean ± SEM; main effect by two-way repeated measures ANOVA of 
both independent variables indicated by *p < 0.05). 
 IV 
  
Fig. 2: Average sickness behaviour scores for non-pregnant females following intravenous (IV) 
administration of poly(I:C) (POL) or saline solution (CON) and subcutaneous (SC) administration 
of 1,25OHD (VITD) or vehicle (VEH). There was a main effect of IV (F1,53=118.801, p<0.0001) 
and SC (F1,53=5.163, p=0.027). LSD post-hoc analysis showed significant differences between 
POL-VEH and CON-VEH as well as POL-VITD and CON-VITD (p<0.0001), in addition to POL-
VEH and POL-VITD (p=0.006). (POL-VEH, n=16; CON-VEH, n=15; POL-VITD, n=12; CON-
VITD, n=14; data are shown as mean ± SEM; main effect by two-way repeated measures 
ANOVA of both independent variables indicated by *p < 0.05). 
Fig. 3: Average sickness behaviour scores for pregnant females following intravenous (IV) 
administration of poly(I:C) (POL) or saline solution (CON) and subcutaneous (SC) administration 
of 1,25OHD (VITD) or vehicle (VEH). There was a main effect of IV (F1,44=206.075, p<0.0001). 
LSD post-hoc analysis showed significant differences between POL-VEH and CON-VEH as well 
as POL-VITD and CON-VITD (p<0.0001). (POL-VEH, n=12; CON-VEH, n=12; POL-VITD, n=10; 
CON-VITD, n=14; data are shown as mean ± SEM; statistical significance indicated by *p < 
0.05). 
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Appendix 3: Sex determination 
 
A representative image of the PCR results used for sex determination: 
 
  Figure 4: Sex determination using Sly/Xlr PCR. The first two samples correspond to female 
(F) and male (M) positive controls, followed by embryonic samples. The expected PCR 
product for the Y chromosome is 280 bp, and larger products ranging between 480 – 685 bp 
for the X chromosome. L = 1-Kb DNA ladder, NTC = non-template control.  
 VI 
Appendix 4: Image processing  
Fig. 5: Outline of image processing required for quantitative analysis. Firstly, using ImageJ raw 
images of the entire midbrain region are cropped to focus on the ventral midbrain and background 
subtraction is performed. Next, images are imported into the CellProfiler pipeline and objects 
(cells) are identified based on nuclear staining. These cells are then filtered according to the 
expression of the fluorescent markers, Lmx1a and Sox2, resulting in two distinct cell populations; 
progenitors (Lmx1a+Sox2+) and postmitotic cells (Lmx1a+Sox2-). 
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 Appendix 5: Accuracy check 
 
In order to assess the accuracy of the automated cell detection of the CellProfiler pipeline, 
cells were manually counted in randomly selected 500x500 pixel regions from three 
images per embryo, using the Cell Counter plug-in in ImageJ. Example images are shown 
below, with representative cells labelled, using the following criteria; 1 = correct (correctly 
identified cell), 2 = reject (correctly rejected cell i.e. when identifying Lmx1a+Sox2+ cells, 
this would be Lmx1a+Sox2-), 3 = false negative (cell incorrectly rejected), 4 = false 
positive (cell incorrectly identified), 5 = over-segmentation (one cell incorrectly segmented 
into smaller ‘cells’), 6 = under-segmentation (two or more cells incorrectly grouped into one 
larger ‘cell’).  
 
 Lmx1a+Sox2+ 
Lmx1a+Sox2- 
1 
2 
3 
4 
5 
6
1 
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Appendix 6: Additional statistics 
 
E11 
 
Progenitors 
 
Measurement 
IV SC 
F p F p 
Cell number * * 0.497 0.486 
Lmx1a expression 1.888 0.179 * * 
Nuclear area 0.297 0.590 0.014 0.907 
Nuclear shape * * 0.007 0.933 
Lateral position 0.037 0.850 1.674 0.206 
Dorsoventral position 0.095 0.760 0.859 0.362 
Total dividing cells 1.743 0.195 * * 
Dividing cells per section 2.092 0.158 * * 
Spindle angle 0.152 0.697 3.220 0.075 
Sox2 expression 1.947 0.173 0.257 0.616 
 
Cell number, Sox2 expression, dividing cells per section df = 1,33 
Lmx1a expression, nuclear area & shape, df = 1,31 
Lateral & dorsoventral position, df = 1,30 
Total dividing cells, df = 1,38 
Spindle angle, df = 1,109 
 
*indicates significant results reported in main text 
 
 
 
 
 
 
 
 IX 
Postmitotic cells 
 
Measurement 
IV SC 
F p F p 
Cell number 0.191 0.665 2.439 0.128 
Lmx1a expression 0.721 0.402 2.734 0.108 
Nuclear area 0.012 0.914 0.779 0.384 
Nuclear shape 0.992 0.327 0.025 0.875 
Lateral position 2.615 0.116 * * 
Dorsoventral position 0.004 0.952 1.102 0.302 
 
Cell number, df = 1,33  
Lmx1a expression, lateral & dorsoventral position, df = 1,31 
Nuclear area & shape, df = 1,32 
 
E14 
 
Progenitors 
 
Measurement 
IV SC 
F p F p 
Cell number 1.354  0.254 0.004  0.951 
Lmx1a expression 0.853 0.363 0.377 0.544 
Nuclear area 0.644 0.429 0.231 0.635 
Nuclear shape 0.951 0.338 0.040 0.842 
Lateral position 0.969 0.333 0.167 0.686 
Dorsoventral position 0.744 0.396 0.175 0.679 
Sox2 expression 0.000 0.989 0.246 0.623 
 
df = 1,29 
 
 
 
 X 
Postmitotic cells 
 
Measurement 
IV SC 
F p F p 
Cell number 0.060 0.808 0.188 0.668 
Lmx1a expression 2.711 0.111 0.280 0.601 
Nuclear area 0.688 0.414 0.219 0.643 
Nuclear shape 0.026 0.874 2.522 0.123 
Lateral position 2.725 0.110 1.503 0.230 
Dorsoventral position 3.294 0.080 2.563 0.121 
 
df = 1,28 
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Appendix 7: Ethics approval 
 
Mice - non genetically modified (C57BL/6J Arc, Female, Juvenile / Weaners / Pouch animal, Commercial breeding 
colony)
9 Dec 2015 Initial approval 138 138
Mice - non genetically modified (C57BL/6J Arc, Mix, Adults, Commercial breeding colony)
9 Dec 2015 Initial approval 206 206
12 Oct 2016 Mod #3 300 506
Mice - non genetically modified (C57BL/6J Arc, Unknown, Prenatal / Embryo, Commercial breeding colony)
9 Dec 2015 Initial approval 123 123
12 Oct 2016 Mod #3 353 476
Description Amount Balance
Approval Details
UQ Research and Innovation
Director, Research Management Office
Nicole Thompson
Animal Ethics Approval Certificate 25-Oct-2016
Please check all details below and inform the Animal Welfare Unit within 10 working days if anything is incorrect.
Activity Details
Chief Investigator: Professor Darryl Eyles, Queensland Brain Institute
Title: Vitamin D rescues the schizophrenia-like phenotype in offspring from Poly:IC treated 
C57Bl6 Dams
AEC Approval Number: QBI/478/15/NHMRC
Previous AEC Number:
Approval Duration: 04-Jan-2016 to 04-Jan-2019
Funding Body:
Group: Anatomical Biosciences
Other Staff/Students: Thomas Burne, Suzy Alexander, Tina Notter, Leon Luan, Suhailah Ali, James Paul Kesby, 
Trish Hitchcock
Summary
Subspecies Strain Class Gender Source Approved Remaining
Mice - non 
genetically 
modified
C57BL/6J Arc Prenatal / Embryo Unknown Commercial 
breeding colony
476 476
Mice - non 
genetically 
modified
C57BL/6J Arc Adults Mix Commercial 
breeding colony
506 506
Mice - non 
genetically 
modified
C57BL/6J Arc Juvenile / Weaners 
/ Pouch animal
Female Commercial 
breeding colony
138 138
Permits
Provisos
Location(s): St Lucia Bldg 79 - Queensland Brain Institute
Cumbrae-Stewart Building
Research Road
Brisbane Qld 4072 Australia
Animal Welfare Unit
UQ Research and Innovation
The University of Queensland
+61 7 336 52925 (Enquiries)
+61 7 334 68710 (Enquiries)
+61 7 336 52713 (Coordinator)
animalwelfare@research.uq.edu.au
uq.edu.au/research
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